Somagen, a US-based multi-omics specialized analysis company, announced on the 5th that it has introduced the latest global sequencing platform UG100™ from Ultima Genomics, a global genome analysis company based in the United States.
Ultima Genomics, established in 2016, is a next-generation global genome analysis company. It is rapidly growing in the global genome analysis market based on its proprietary next-generation sequencing (NGS) technology.
The UG100™ platform from Ultima Genomics, adopted by Somagen, is an innovative genome analysis platform that surpasses existing next-generation sequencing (NGS) technologies, based on an enhanced sequencing architecture.
Compared to existing sequencing platforms from global genome analysis companies such as Illumina, UG100™ is characterized by drastically reducing costs while maintaining high accuracy. Additionally, UG100™ was recently selected as the official genome analysis platform for a large-scale human proteome research project conducted by the UK Biobank.
The variant detection function using UG100™’s ppmSeq™ (paired plus minus sequencing) technology reduces the error rate to one part per million compared to existing technologies. It demonstrates excellent performance in tumor genomics and minimal residual disease (MRD) monitoring fields, where precise variant analysis is essential. It is also expected to enable more economical single-cell genome analysis with higher resolution than existing sequencing platforms in single-cell and spatial biology analyses.
Hong Soo, CEO of Somagen, emphasized, “We have secured the capability to analyze more than 30,000 genomes annually at high resolution,” adding, “We will expand Somagen’s market share in the rapidly growing $13 billion global single-cell research market.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
